The cerebrovascular disease is the most common cause for death or adult disability among Chinese population. The High-Risk Non-Disabling Ischemic Cerebrovascular Events (HR-NICE) are very common, and they are unstable in early phases, with good prognosis after effective treatment. In recent years, the HR-NICE has gradually attracted worldwide attentions. Our work has focused on the patients with the highest stroke risk, the most effective antithrombotic therapy, and the most appropriate individualized treatment for more than 10 years. In this paper, we review the early recognition, the diagnosis and the treatment of the HR-NICE.
WANG Yilong
,
JIA Qian
,
WANG Yongjun
. High-risk non-disabling ischemic cerebrovascular events (HR-NICE): A new target for aggressive treatment[J]. Science & Technology Review, 2017
, 35(4)
: 31
-35
.
DOI: 10.3981/j.issn.1000-7857.2017.04.004
[1] Johnston S C, Mendis S, Mathers C D. Global variation in stroke bur-den and mortality:Eestimates from monitoring, surveillance, and model-ling[J]. Lancet Neurology, 2009, 8(4):345-354.
[2] Wang Y, Zhao X, Jiang Y, et al. Prevalence, knowledge, and treatment of transient ischemic attacks in china[J]. Neurology, 2015, 84(23):2354-2361.
[3] Li J, Wang Y, Lin J, et al. Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic at-tack[J]. Stroke, 2015:strokeaha.115.008685.
[4] Lin J, Zheng H, Cucchiara B L, et al. Association of lp-pla2-a and early recurrence of vascular events after tia and minor stroke[J]. Neurol-ogy, 2015, 85(18):1585-1591.
[5] Wang Y, Zhao X, Liu L, et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China:The chinese intracranial atherosclerosis (cicas) study[J]. Strok, 2014, 45(3):663-669.
[6] Amarenco P, Lavallée P C, Labreuche J. One-year risk of stroke after transient ischemic attack or minor stroke[J]. New England Journal of Medicine, 2016, 374(16):1533-1542.
[7] Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute mi-nor stroke or transient ischemic attack[J]. The New England Journal of Medicine, 2013, 369:11-19.
[8] Wang Y, Pan Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial:One-year outcomes[J]. Circulation, 2015, 132:40-46.
[9] Wang X, Zhao X, Johnston S C, et al. Effect of clopidogrel with aspirin on functional outcome in tia or minor stroke:Chance substudy[J]. Neu-rology, 2015, 85(7):573-579
[10] Wang Y, Zhao X, Lin J, et al. Association between CYP2C19 loss-offunction allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack[J]. JA-MA, 2016, 316(1):70-78.
[11] Li J, Wang Y, Wang D, et al. Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke[J]. Neurology, 2015, 84(13):1330-1336.
[12] Zhou Y, Pan Y, Wu Y, et al. Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack[J]. Stroke, 2016, 47(11):2791-2796.
